Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD

Cancer Immunology, Immunotherapy

Volumn 58, Issue 12, 2009, Pages 2073-2084

  Ash, Shifra ^a   Gigi, Vered ^a,b   Askenasy, Nadir ^a   Fabian, Ina ^b   Stein, Jerry ^a   Yaniv, Isaac ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Allogeneic; Bone marrow transplantation; MHC disparity; Neuroblastoma; Syngeneic

Indexed keywords

EPITOPE; HISTOCOMPATIBILITY ANTIGEN;

A J MOUSE; ANIMAL; ARTICLE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL GROWTH; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; METHODOLOGY; MOUSE; MOUSE MUTANT; NEUROBLASTOMA; NONOBESE DIABETIC MOUSE; PATHOLOGY; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL GROWTH PROCESSES; EPITOPES; GRAFT VS TUMOR EFFECT; HISTOCOMPATIBILITY ANTIGENS; IMMUNOTHERAPY; MICE; MICE, INBRED A; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; NEUROBLASTOMA; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING;

EID: 78149469328     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0715-6     Document Type: Article

References (52)

1. Ladenstein R, Pötschger U, Hartman O, EBMT Paediatric Working Party et al (2008) 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 41(Suppl 2):S118-S127 (Pubitemid 351864722)
2. Kanold J, Yakouben K, Tchirkov A et al (2000) Long-term results of CD34(+) cell transplantation in children with neuroblastoma. Med Pediatr Oncol 35:1-7 (Pubitemid 30447817)
3. Burchill SA, Kinsey SE, Picton S et al (2001) Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol 36:213-219
4. Bowman LC, Grossmann M, Rill D et al (1998) Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 9:1303-1311 (Pubitemid 28312895)
5. Lode HN, Xiang R, Dreier T et al (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706-1715 (Pubitemid 28110336)
6. Haight AE, Bowman LC, Ng CY et al (2000) Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy. Med Pediatr Oncol 35:712-715
7. Slavin S, Morecki S, Weiss L, Or R (2002) Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res 11:265-276 (Pubitemid 34309520)
8. Kanold J, Paillard C, Tchirkov A et al (2008) Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model. Bone Marrow Transplant 42(Suppl 2):S25-S30
9. Teshima T, Mach N, Hill GR et al (2001) Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 61:162-171 (Pubitemid 32095714)
10. Inoue M, Nakano T, Yoneda A et al (2003) Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant 32:103-106 (Pubitemid 36850287)
11. Li JM, Waller EK (2004) Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 10:540-551
12. Hirayama M, Azuma E, Araki M et al (2006) Evidence of graft-versus-tumor effect in refractory metastatic neuroblastoma. Transplantation 82:142-144 (Pubitemid 44296994)
13. Sykulev Y, Joo M, Vturina I et al (1996) Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4:565-571 (Pubitemid 26233310)
14. Main EK, Lampson LA, Hart MK et al (1985) Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol 135:242-246 (Pubitemid 15011436)
15. Coze C, Aalto-Setala K, Brenner M, Chiang Y (1995) Characteristics and immunomodulatory properties of human neuroblastoma cells after retrovirus-mediated gene transfer of the cytokine genes IL-2 and IFN-gamma. Transgenics 1:585-595
16. Ponzoni M, Guarnaccia F, Corrias MV, Cornaglia-Ferraris P (1993) Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells. Int J Cancer 55:817-823 (Pubitemid 23354900)
17. Murphy C, Nikodem D, Howcroft K et al (1996) Active repression of major histocompatibility complex class I genes in a human neuroblastoma cell line. J Biol Chem 271:30992-30999 (Pubitemid 26404128)
18. Wolfl M, Jungbluth AA, Garrido F et al (2005) Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 54:400-406 (Pubitemid 40238934)
19. Evans A, Main E, Zier K et al (1989) The effects of gamma interferon on the natural killer and tumor cells of children with neuroblastoma: a preliminary report. Cancer 64:1383-1387 (Pubitemid 19238948)
20. Lampson LA, Whelan JP, Fisher CA (1985) HLA-A, B, C and beta 2-microglobulin are expressed weakly by human cells of neuronal origin, but can be induced in neuroblastoma cell lines by interferon. Prog Clin Biol Res 175:379-388
21. Sugimoto T, Horii Y, Hino T et al (1989) Differential susceptibility of HLA class II antigens induced by gammainterferon in human neuroblastoma cell lines. Cancer Res 49:1824-1828 (Pubitemid 19108411)
22. Hock H, Dorsch M, Kunzendorf U et al (1993) Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 90:2774-2778 (Pubitemid 23113499)
23. Sadanaga N, Nagoshi M, Lederer JA et al (1999) Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells. J Immunother 22:315-323 (Pubitemid 29309964)
24. Katsanis E, Orchard PJ, Bausero MA et al (1994) Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother 15:81-90 (Pubitemid 24047540)
25. Bauer M, Reaman GH, Hank JA et al (1995) A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 75:2959-2965
26. Bowman L, Grossmann M, Rill D et al (1998) IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92:1941-1949 (Pubitemid 28446683)
27. Rousseau RF, Haight AE, Hirschmann-Jax C et al (2003) Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101:1718-1726 (Pubitemid 36237566)
28. Pearl-Yafe M, Yolcu ES, Stein J et al (2007) Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Exp Hematol 35:1601-1612 (Pubitemid 47419142)
29. Barker SE, Grosse SM, Siapati EK et al (2007) Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12. Br J Cancer 97:210-217 (Pubitemid 47057478)
30. Christinck ER, Luscher MA, Barber BH, Williams DB (1991) Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352:67-70 (Pubitemid 21896699)
31. Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN (1995) Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 154:567-576
32. Foss FM (2002) Immunologic mechanisms of antitumor activity. Semin Oncol 29:5-11
33. Saito M, Yu RK, Cheung NK (1985) Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Commun 127:1-7 (Pubitemid 15146924)
34. Croce M, Meazza R, Orengo AM et al (2008) Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother 57:1625-1634
35. Sugimoto T, Tatsumi E, Kemshead JT et al (1984) Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies. J Natl Cancer Inst 73:51-57 (Pubitemid 14090827)
36. Schonmann SM, Iyer J, Laeng H et al (1986) Production and characterization of monoclonal antibodies against human neuroblastoma. Int J Cancer 37:255-262 (Pubitemid 16152450)
37. Takagi S, Fujikawa K, Imai T et al (1995) Identification of a highly specific surface marker of T-cell acute lymphoblastic leukemia and neuroblastoma as a new member of the transmembrane 4 superfamily. Int J Cancer 61:706-715
38. Castriconi R, Dondero A, Augugliaro R et al (2004) Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 101:12640-12645 (Pubitemid 39122076)
39. Morisaki T, Matsumoto K, Onishi H et al (2003) Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 16:175-182
40. Redlinger RE Jr, Mailliard RB, Barksdale EM Jr (2004) Neuroblastoma and dendritic cell function. Semin Pediatr Surg 13:61-71 (Pubitemid 38233860)
41. Fujii S (2008) Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol 29:242-249
42. Fernandez NC, Lozier A, Flament C et al (1999) Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5:405-411 (Pubitemid 29180578)
43. Shimizu T, Berhanu A, Redlinger RE Jr et al (2001) Watkins S, Lotze MT, Barksdale EM Jr. Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J Pediatr Surg 36:1285-1292 (Pubitemid 32705726)
44. Castriconi R, Dondero A, Cilli M et al (2007) Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 56:1733-1742 (Pubitemid 47313078)
45. Shurin GV, Shurin MR, Bykovskaia S et al (2001) Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61:363-369 (Pubitemid 32095739)
46. Redlinger RE Jr, Mailliard RB, Barksdale EM Jr (2003) Advanced neuroblastoma impairs dendritic cell function in adoptive immunotherapy. J Pediatr Surg 38:857-862 (Pubitemid 36666278)
47. Yang L, Carbone DP (2004) Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13-27 (Pubitemid 39458111)
48. Walker SR, Redlinger RE Jr, Barksdale EM Jr (2005) Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression. J Pediatr Surg 40:244-250 (Pubitemid 40143566)
49. Shurin GV, Gerein V, Lotze MT, Barksdale EM Jr (1998) Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand. Nat Immun 16:263-274
50. Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117-158 (Pubitemid 32959264)
51. Slavin S, Aker M, Shapira MY et al (2003) Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. Clin Transpl 275-282
52. Stein J, Dini G, Yaniv I, Pediatric Diseases Working Party of the EBMT (2005) The hope and the reality of reduced intensity transplants in children with malignant diseases. Bone Marrow Transplant 35(Suppl 1):S39-S43 (Pubitemid 40613921)